4-15587928-AG-A
Variant summary
Our verdict is Pathogenic. Variant got 20 ACMG points: 20P and 0B. PVS1PM2PP3_ModeratePP5_Very_Strong
The NM_001378615.1(CC2D2A):c.4179+1del variant causes a frameshift, splice region change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000767 in 1,578,048 control chromosomes in the GnomAD database, with no homozygous occurrence. 1/1 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_001378615.1 frameshift, splice_region
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 20 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CC2D2A | NM_001378615.1 | c.4179+1del | frameshift_variant, splice_region_variant | 32/37 | ENST00000424120.6 | NP_001365544.1 | ||
CC2D2A | NM_001080522.2 | c.4179+1del | frameshift_variant, splice_region_variant | 33/38 | NP_001073991.2 | |||
CC2D2A | NM_001378617.1 | c.4032+1del | frameshift_variant, splice_region_variant | 30/35 | NP_001365546.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CC2D2A | ENST00000424120.6 | c.4179+1del | frameshift_variant, splice_region_variant | 32/37 | 5 | NM_001378615.1 | ENSP00000403465 | P1 |
Frequencies
GnomAD3 genomes AF: 0.000184 AC: 28AN: 152138Hom.: 0 Cov.: 31
GnomAD3 exomes AF: 0.0000931 AC: 23AN: 247170Hom.: 0 AF XY: 0.0000969 AC XY: 13AN XY: 134098
GnomAD4 exome AF: 0.0000652 AC: 93AN: 1425792Hom.: 0 Cov.: 24 AF XY: 0.0000661 AC XY: 47AN XY: 711328
GnomAD4 genome AF: 0.000184 AC: 28AN: 152256Hom.: 0 Cov.: 31 AF XY: 0.000295 AC XY: 22AN XY: 74458
ClinVar
Submissions by phenotype
Meckel syndrome, type 6 Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jan 29, 2024 | Variant summary: CC2D2A c.4179+1delG is located in a canonical splice-site and is predicted to affect mRNA splicing resulting in a significantly altered protein due to either exon skipping, shortening, or inclusion of intronic material. Several computational tools predict a significant impact on normal splicing: Three predict the variant abolishes a canonical 5' splicing donor site, and two predict the variant creates a cryptic 5' donor site. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 9.3e-05 in 247170 control chromosomes (gnomAD). This frequency is not significantly higher than estimated for a pathogenic variant in CC2D2A causing Meckel Syndrome Type 6 (9.3e-05 vs 0.0011), allowing no conclusion about variant significance. c.4179+1delG has been reported in the literature in individuals affected with Meckel Syndrome or Joubert Syndrome (Mougou-Zerelli_2009, Tallila_2009, Bachmann-Gagescu_2015). These data indicate that the variant is likely to be associated with disease. The following publications have been ascertained in the context of this evaluation (PMID: 19777577, 19466712, 26092869). ClinVar contains an entry for this variant (Variation ID: 56312). Based on the evidence outlined above, the variant was classified as pathogenic. - |
Likely pathogenic, no assertion criteria provided | literature only | Juha Muilu Group; Institute for Molecular Medicine Finland (FIMM) | - | - - |
Likely pathogenic, no assertion criteria provided | literature only | Juha Muilu Group; Institute for Molecular Medicine Finland (FIMM) | - | - - |
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Apr 27, 2022 | Canonical splice site variant expected to result in aberrant splicing, although in the absence of functional evidence the actual effect of this sequence change is unknown.; This variant is associated with the following publications: (PMID: 31589614, 33486889, 19777577, 26092869, 19466712) - |
Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Mar 14, 2016 | - - |
Joubert syndrome 9 Pathogenic:2
Pathogenic, criteria provided, single submitter | research | UW Hindbrain Malformation Research Program, University of Washington | Feb 23, 2015 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Centre for Mendelian Genomics, University Medical Centre Ljubljana | Jan 01, 2016 | This variant was classified as: Pathogenic. The following ACMG criteria were applied in classifying this variant: PVS1,PS1,PM2,PP4. - |
Meckel-Gruber syndrome;C0431399:Familial aplasia of the vermis Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 22, 2024 | This sequence change affects a splice site in intron 33 of the CC2D2A gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in CC2D2A are known to be pathogenic (PMID: 19777577). This variant is present in population databases (rs386833761, gnomAD 0.09%). Disruption of this splice site has been observed in individual(s) with Joubert and/or Meckel-Gruber syndrome (PMID: 19777577, 26092869). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. This variant is also known as c.4179del. ClinVar contains an entry for this variant (Variation ID: 56312). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. - |
Joubert syndrome 9;C2676790:Meckel syndrome, type 6;C5436837:COACH syndrome 2;C5676970:Retinitis pigmentosa 93 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Feb 14, 2022 | - - |
Inborn genetic diseases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Dec 16, 2021 | The c.4179+1delG variant results from a deletion of one nucleotide at position c.4179+1 and involves the canonical splice donor site after coding exon 31 of the CC2D2A gene. Alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. Based on data from gnomAD, the - allele has an overall frequency of 0.01% (23/247170) total alleles studied. The highest observed frequency was 0.09% (9/9980) of Ashkenazi Jewish alleles. This mutation has been identified in 2 compound heterozygous individuals with Joubert syndrome as well as 2 compound heterozygous fetuses with Meckel syndrome (Mougou-Zerelli, 2009; Tallila, 2009; Bachmann-Gagescu, 2015). Based on the available evidence, this alteration is classified as pathogenic. - |
Clubfoot;C0022680:Polycystic kidney disease;C0079924:Oligohydramnios;C0426790:Narrow chest;C4282400:Polydactyly, postaxial, type A1;C4551563:Microcephaly;C4551722:Encephalocele Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Centre for Mendelian Genomics, University Medical Centre Ljubljana | Jan 01, 2017 | - - |
Meckel-Gruber syndrome Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | Genetic Services Laboratory, University of Chicago | Sep 22, 2014 | - - |
Anencephaly;C0152427:Polydactyly;C3887499:Renal cyst Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Genetics Institute, Tel Aviv Sourasky Medical Center | May 12, 2021 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at